Platelets modulate gastric ulcer healing: Role of endostatin and vascular endothelial growth factor release
Open Access
- 15 May 2001
- journal article
- Published by National Academy of Sciences in Proceedings of the National Academy of Sciences
- Vol. 98 (11) , 6470-6475
Abstract
Bleeding and delayed healing of ulcers are well recognized clinical problems associated with the use of aspirin and other nonsteroidal antiinflammatory drugs, which have been attributed to their antiaggregatory effects on platelets. We hypothesized that antiplatelet drugs might interfere with gastric ulcer healing by suppressing the release of growth factors, such as vascular endothelial growth factor (VEGF), from platelets. Gastric ulcers were induced in rats by serosal application of acetic acid. Daily oral treatment with vehicle, aspirin, or ticlopidine (an ADP receptor antagonist) was started 3 days later and continued for 1 week. Ulcer induction resulted in a significant increase in serum levels of VEGF and a significant decrease in serum levels of endostatin (an antiangiogenic factor). Although both aspirin and ticlopidine markedly suppressed platelet aggregation, only ticlopidine impaired gastric ulcer healing and angiogenesis as well as reversing the ulcer-associated changes in serum levels of VEGF and endostatin. The effects of ticlopidine on ulcer healing and angiogenesis were mimicked by immunodepletion of circulating platelets, and ticlopidine did not influence ulcer healing when given to thrombocytopenic rats. Incubation of human umbilical vein endothelial cells with serum from ticlopidine-treated rats significantly reduced proliferation and increased apoptosis, effects reversed by an antibody directed against endostatin. Ticlopidine treatment resulted in increased platelet endostatin content and release. These results demonstrate a previously unrecognized contribution of platelets to the regulation of gastric ulcer healing. Such effects likely are mediated through the release from platelets of endostatin and possibly VEGF. As shown with ticlopidine, drugs that influence gastric ulcer healing may do so in part through altering the ability of platelets to release growth factors.Keywords
This publication has 38 references indexed in Scilit:
- The in vivo pharmacological profile of CS‐747, a novel antiplatelet agent with platelet ADP receptor antagonist propertiesBritish Journal of Pharmacology, 2000
- Evidence that platelets promote tube formation by endothelial cells on matrigelBritish Journal of Pharmacology, 1998
- The vascular endothelial growth factor family; proteins which guide the development of the vasculatureInternational Journal of Experimental Pathology, 1998
- Protective Effects of Ticlopidine and Aspirin, Administered Alone and in Combination, on Thrombus Formation in Rat Cerebral VesselsPathophysiology of Haemostasis and Thrombosis, 1996
- Anti-thrombotic effects of a nitric oxide-releasing, gastric-sparing aspirin derivative.Journal of Clinical Investigation, 1995
- A nitric oxide-releasing nonsteroidal anti-inflammatory drug accelerates gastric ulcer healing in ratsGastroenterology, 1995
- SR 25989 inhibits healing of a mechanical wound of confluent human saphenous vein endothelial cells which is modulated by standard heparin and growth factorsJournal of Cellular Physiology, 1994
- Quality of Gastric Ulcer HealingJournal of Clinical Gastroenterology, 1991
- Thrombin structure and functionBlood Coagulation & Fibrinolysis, 1991
- High-yield purification of platelet-derived endothelial cell growth factor: structural characterization and establishment of a specific antiserumBiochemistry, 1989